UNSPSC 51341505: Fosamprenavir calcium

This classification denotes a protease inhibitor C25H34N3O9PS.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ID1GU2627N, chemically known as (3s)-tetrahydro-3-furyl ((.alpha.s)-.alpha.-((1r)-1-hydroxy-2-(n1-isobutylsulfanilamido)ethyl)phenethyl)carbamate, calcium phosphate (ester) (1:1), but more generally known as fosamprenavir calcium, which bears US NIH Compound Identifier 131535. European Medicines Agency schedules Fosamprenavir calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20055.

UNSPSC 51341505 Fosamprenavir calcium is a Commodity code that nominally identifies a specific antiretroviral pharmaceutical agent, but recent state and local procurement activity tagged under this code does not reflect purchasing of fosamprenavir itself. Instead, the opportunities posted under this code span emergency medical supplies, pharmaceutical distribution infrastructure, and naloxone procurement—work substantially unrelated to the code's nominal scope. State and local governments use this code to solicit medical consumables, naloxone and drug deactivation systems, generic pharmaceuticals through cooperative purchasing arrangements, and first-aid supplies for emergency response divisions. The issuing bodies include county health departments (Seminole County, Florida), city fire departments (Tampa), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, which includes Oregon).

Recent activity spans Florida, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries due by July 26, 2023; the City of Tampa's IFB for medical and first-aid supplies (169 line items including respiratory equipment, cardiac monitoring electrodes, and medical consumables) for the Tampa Fire Department Rescue Division, with bids due March 13, 2026, estimated at $700,000 and designated as a sheltered market for certified Small Local Business Enterprises with a 5 percent bid discount; the Texas HHS Commission's RFI for direct-to-manufacturer prescription programs seeking vendor capabilities for therapeutic pharmacy initiatives, with responses due April 3, 2026; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and awards effective July 1, 2026. The mismatch between the code's pharmaceutical-specific name and the actual scope of recent opportunities suggests this Commodity code is being applied inconsistently by posting agencies or that state and local procurement offices are using it as a catch-all for health-related supplies and pharmaceutical distribution work outside its intended taxonomic purpose.